Yazar "Bilgetekin, I." için listeleme
-
Antiangiogenic therapy in ovarian cancer for whom and when?
Bilgetekin, I.; Cetin, B.; Ozet, A. (Medical Communications, 2017)Tumor angiogenesis appears to be an important process in epithelial ovarian cancer development. Bevacizumab is a monoclonal antibody that can neutralize vascular endothelial growth factor, a promoter of the initiation phase ... -
Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence
Cetin, B.; Bilgetekin, I.; Cengiz, M.; Ozet, A. (Springer International Publishing, 2017)Vascular endothelial growth factor (VEGF) plays an important role in the growth of tumor cells, and in their invasion, metastasis, and angiogenesis. Kinase inhibitors (which are taken orally, work intracellularly, and can ...